EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Biomechanical profile of cancer stem-like/tumor-initiating cells derived from a progressive ovarian cancer model



Biomechanical profile of cancer stem-like/tumor-initiating cells derived from a progressive ovarian cancer model



Nanomedicine 10(5): 1013-1019



We herein report, for the first time, the mechanical properties of ovarian cancer stem-like/tumor-initiating cells (CSC/TICs). The represented model is a spontaneously transformed murine ovarian surface epithelial (MOSE) cell line that mimics the progression of ovarian cancer from early/non-tumorigenic to late/highly aggressive cancer stages. Elastic modulus measurements via atomic force microscopy (AFM) illustrate that the enriched CSC/TICs population (0.32±0.12kPa) are 46%, 61%, and 72% softer (P<0.0001) than their aggressive late-stage, intermediate, and non-malignant early-stage cancer cells, respectively. Exposure to sphingosine, an anti-cancer agent, induced an increase in the elastic moduli of CSC/TICs by more than 46% (0.47±0.14kPa, P<0.0001). Altogether, our data demonstrate that the elastic modulus profile of CSC/TICs is unique and responsive to anti-cancer treatment strategies that impact the cytoskeleton architecture of cells. These findings increase the chance for obtaining distinctive cell biomechanical profiles with the intent of providing a means for effective cancer detection and treatment control. This novel study utilized atomic force microscopy to demonstrate that the elastic modulus profile of cancer stem cell-like tumor initiating cells is unique and responsive to anti-cancer treatment strategies that impact the cytoskeleton of these cells. These findings pave the way to the development of unique means for effective cancer detection and treatment control.

(PDF emailed within 0-6 h: $19.90)

Accession: 051816111

Download citation: RISBibTeXText

PMID: 24407147

DOI: 10.1016/j.nano.2013.12.009



Related references

Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells. Plos One 6(8): E23383-E23383, 2011

Photodynamic therapy with 5-aminolevulinic acid (ALA) impairs tumor initiating and chemo-resistance property in head and neck cancer-derived cancer stem cells. Plos One 9(1): E87129-E87129, 2015

Distinct populations of tumor-initiating cells derived from a tumor generated by rat mammary cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America 105(44): 16940-5, 2008

Regulation of ovarian cancer stem cells or tumor-initiating cells. International Journal of Molecular Sciences 14(4): 6624-6648, 2013

Biomechanical profile of cancer stem-like cells derived from MHCC97H cell lines. Journal of Biomechanics 49(1): 45-52, 2016

Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells. Anticancer Research 34(9): 4723-4731, 2014

Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clinical Cancer Research, 2018

POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells. International Journal of Cancer 140(11): 2517-2525, 2017

Hepatitis C virus-induced tumor-initiating cancer stem-like cells activate stromal fibroblasts in a xenograft tumor model. Hepatology 66(6): 1766-1778, 2017

Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Research 69(22): 8555-8562, 2009

Tumor initiating cancer stem cells from human breast cancer cell lines. International Journal of Oncology 34(5): 1449-1453, 2009

DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells. Journal of Cellular and Molecular Medicine: -, 2018

Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. Bmc Cancer 12: 359-359, 2013

Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Molecular Cancer Therapeutics 10(10): 1829-1838, 2012

Linneg Sca-1high CD49fhigh prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential in vitro and in vivo. Oncotarget 7(18): 25194-25207, 2018